Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr

U Subotic; S Hosie; K L Waag; K Reinshagen

doi:10.1055/s-2008-1073158

Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr

Standard

Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr. / Subotic, U; Hosie, S; Waag, K L; Reinshagen, K.

In: KLIN PADIATR, Vol. 220, No. 4, 26.07.2008, p. 248-52.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Subotic, U, Hosie, S, Waag, KL & Reinshagen, K 2008, 'Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr', KLIN PADIATR, vol. 220, no. 4, pp. 248-52. https://doi.org/10.1055/s-2008-1073158

APA

Subotic, U., Hosie, S., Waag, K. L., & Reinshagen, K. (2008). Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr. KLIN PADIATR, 220(4), 248-52. https://doi.org/10.1055/s-2008-1073158

Vancouver

Subotic U, Hosie S, Waag KL, Reinshagen K. Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr. KLIN PADIATR. 2008 Jul 26;220(4):248-52. https://doi.org/10.1055/s-2008-1073158

Bibtex

@article{fcf0e00238ee417eb810f0809f5a7bc3,

title = "Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr",

abstract = "BACKGROUND: The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants.PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years.RESULTS: During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients.CONCLUSIONS: Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.",

keywords = "Antineoplastic Agents, Chemotherapy, Adjuvant, Chylothorax, Combined Modality Therapy, Female, Head and Neck Neoplasms, Humans, Infant, Infant, Newborn, Injections, Intralesional, Lymphangioma, Cystic, Male, Neoplasm Recurrence, Local, Picibanil, Postoperative Complications, Retrospective Studies, English Abstract, Journal Article",

author = "U Subotic and S Hosie and Waag, {K L} and K Reinshagen",

year = "2008",

month = jul,

day = "26",

doi = "10.1055/s-2008-1073158",

language = "Deutsch",

volume = "220",

pages = "248--52",

journal = "KLIN PADIATR",

issn = "0300-8630",

publisher = "Georg Thieme Verlag KG",

number = "4",

}

RIS

TY - JOUR

T1 - Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr

AU - Subotic, U

AU - Hosie, S

AU - Waag, K L

AU - Reinshagen, K

PY - 2008/7/26

Y1 - 2008/7/26

N2 - BACKGROUND: The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants.PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years.RESULTS: During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients.CONCLUSIONS: Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.

AB - BACKGROUND: The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants.PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years.RESULTS: During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients.CONCLUSIONS: Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.

KW - Antineoplastic Agents

KW - Chemotherapy, Adjuvant

KW - Chylothorax

KW - Combined Modality Therapy

KW - Female

KW - Head and Neck Neoplasms

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - Injections, Intralesional

KW - Lymphangioma, Cystic

KW - Male

KW - Neoplasm Recurrence, Local

KW - Picibanil

KW - Postoperative Complications

KW - Retrospective Studies

KW - English Abstract

KW - Journal Article

U2 - 10.1055/s-2008-1073158

DO - 10.1055/s-2008-1073158

M3 - SCORING: Zeitschriftenaufsatz

C2 - 18654945

VL - 220

SP - 248

EP - 252

JO - KLIN PADIATR

JF - KLIN PADIATR

SN - 0300-8630

IS - 4

ER -